The Latest Breaking News on Pharma

The Supreme Court is reconsidering the accessibility of popular abortion drug, Mifepristone, a high-stakes case with potential electoral repercussions.

Committee recommends revising UCPMP to prohibit CMEs in foreign locations, disclose price of gifts to doctors, and make money received by doctors from pharma cos for research taxable.

U.S. health officials grapple with inadequate inspection of overseas eyedrop factories, leading to recalls of potentially dangerous products.

Repeated recalls of eyedrops are drawing new attention to the limited powers U.S. regulators have to oversee medical products made overseas

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business

Citius Pharmaceuticals (CTXR) has been making significant progress in its pipeline, garnering investors' attention. However, considering that CTXR is an unprofitable and pre-revenue business, is it worth investing now as the company prepares to report quarterly results? Keep reading.

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

The pharmaceutical industry is well-positioned for robust growth, driven by growing healthcare expenditure globally and the rapid adoption of digital technologies. Given the industry’s tailwinds, fundamentally strong pharma stocks, Collegium Pharmaceutical (COLL), Eton Pharmaceuticals (ETON), and GSK plc (GSK) could be ideal buys this month. Continue Reading….

‘He’s one of the few presidents that got almost everything right. He understood the proper role of the federal government under the Constitution,’ DeSantis says

DCA busts spurious anti-cancer drug racket, ₹4.35 crore stock seized 

Editorial: Patients are facing shorter lives as drug companies are demanding prices that health services here and in other countries cannot pay